Fat-soluble vitamin
CCP: Major, life-threatening hemorrhage in patients with an INR > 1.5, on warfarin therapy, or with vitamin K deficiency
CCP: Major, life-threatening hemorrhage in patients with an INR > 1.5, on warfarin therapy, or with vitamin K deficiency
CCP: Major, life-threatening hemorrhage in patients with an INR > 1.5, on warfarin therapy, or with vitamin K deficiency
Promotes liver synthesis of clotting factors (II, VII, IX, X); however, the exact mechanism as to this stimulation is unknown.
Intravenous:
Fatal hypersensitivity reactions, including anaphylaxis, have occurred with parenteral use; onset may occur during or immediately after intravenous (IV) or intramuscular (IM) administration. Reactions have occurred despite dilution to avoid rapid IV infusion and with the first dose.